肿瘤标志联合检测在肺癌辅助诊断中的应用

Application of combined detection of tumor markers in the aided diagnosis of lung cancer

目的评价肿瘤标志癌胚抗原（CEA）、神经元特异性烯醇化酶（NSE）、鳞状上皮细胞癌抗原（SCC-Ag）、细胞角蛋白19片断（CYFRA21-1）和p16基因甲基化在肺癌辅助诊断中的价值。方法应用ELISA试剂盒分别测定肺癌患者、非良性疾病患者及健康者血清中的CEA、NSE、SCC．Ag及CYFRA21—1水平，采用甲基化特异性PCR检测血浆中p16甲基化情况；同时运用Fisher判别法探讨该5种肿瘤标志在肺癌辅助诊断中的意义。结果应用Fisher线性判别分析对全部样本判别的灵敏度分别为61．9％（26／42），特异度为92．0％（80／87），准确度为76．7％（99／129），阳性预测值为78．8％（26／33），阴性预测值为75．5％（80／106）。结论该5种肿瘤标志在肺癌辅助诊断方面有一定的参考价值。

Objective To investigate the value of detection of five tumor markers （ CEA, NSE, SCC-Ag, CYFRA21-1 and p16 methylation） on the aided diagnosis of lung cancer. Methods The ser- um levels of CEA, NSE, SCC-Ag and CYFRA21-1 were detected in lung cancer patients, malignant dis- ease patients, and healthy people by the kits, p16 was detected by methylation specific PCR. The dis- criminant model was established by Fisher method. Results The sensitivity of the Fisher model for all samples was 61.9% （26/42）, the specificity was 92. 0% （80/87）, the accuracy was 76. 7% （99/129）, the positive predictive value was 78.8 % （26/33）, the negative predictive value was 75.5 % （80/106）. Conclusions Combined detection of the five tumor markers can provide useful information for the diag- nosis of lung cancer.